Silence Therapeutics files SPC case against Alnylam

Biotech company Silence Therapeutics has filed a case on supplementary protection certificates (SPCs) at the English Patents Court against Alnylam and The Medicines Company.

Announced on Monday, July 3, the claim asks the court to determine whether Silence is entitled to SPCs on certain late-stage products made by the companies.

The drugs include Patisiran, Fitusiran and Givosiran, all of which are RNAi therapeutic treatments.

Noting that SPC protection would extend its IP rights, the company said in a statement: “We reiterate … that we consider potential licences under our patent estate could have a significant financial effect relative to the current market capitalisation of Silence.

“As such, we consider the commencement of this process to be the next step in realising this value.”

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.